Clinically give differential diagnosis of endometriosis , adenomyosis ,endometrial hyperplasia , endometrial cancer , endometrial stromal tumor , leiomyoma with respect to pathology

Reading File

Now I'll run parallel searches across the library for all six conditions:

Finding Sources

Good. Now let me read the key pathology sections in parallel:

Reading File

Finding Sources

Now let me read the endometrial carcinoma, leiomyoma (uterine), and endometrial stromal tumor sections:

Reading File

Finding Sources

I have enough textbook content. Now let me read the leiomyoma and endometrial stromal tumor sections from earlier results, and also the endometriosis morphology section:

Reading File

I now have comprehensive pathology data from Robbins & Kumar Basic Pathology and Robbins, Cotran & Kumar Pathologic Basis of Disease. I also have detailed sections on leiomyoma and endometrial stromal tumor. Let me compile the full differential diagnosis:

Reading File

I now have sufficient pathology content from Robbins. Let me now compose the comprehensive clinical differential diagnosis with respect to pathology.

Clinical Differential Diagnosis of Uterine/Endometrial Conditions - Pathological Basis

Below is a systematic comparison of all six conditions across the key pathological parameters that drive clinical differentiation. Sources: Robbins & Kumar Basic Pathology (9780323790185) and Robbins, Cotran & Kumar Pathologic Basis of Disease (9780443264528).

1. ENDOMETRIOSIS

Pathological Definition

Presence of endometrial glands AND stroma outside the uterus - most commonly on ovaries, uterine ligaments, rectovaginal septum, cul-de-sac, and pelvic peritoneum. Three subtypes: superficial peritoneal, ovarian (endometrioma), and deep infiltrating endometriosis.

Gross Pathology

Superficial implants: Red/blue/black "powder-burn" lesions on peritoneal surfaces
Ovarian endometrioma: "Chocolate cyst" - cyst filled with old hemorrhagic material resembling chocolate syrup; wall contains endometrial glands and stroma
Deep infiltrating: Firm, fibrotic nodules in rectovaginal septum, uterosacral ligaments; can invade rectum, bladder
Repeated cyclic hemorrhage leads to dense fibrous adhesions that distort pelvic anatomy

Microscopic Pathology

Ectopic foci contain all three components of functional endometrium: glands, stroma, and hemosiderin-laden macrophages (diagnostic triad)
Glands respond to hormonal stimulation (proliferative/secretory changes)
Surrounding fibrosis and hemosiderin deposition (siderophages)
Stroma has characteristic small, dark stromal cells with scanty cytoplasm
In old lesions, glands may be obliterated leaving only stroma + hemosiderin
Malignant transformation: rare (~1%), mainly in ovarian endometriosis -> endometrioid or clear cell carcinoma

Molecular/Pathogenesis

Elevated aromatase -> local estrogen production
Increased prostaglandin E2, VEGF, MMPs
Progesterone resistance at the stromal cell level
Retrograde menstruation + immune failure to clear implants

Clinical Correlation

Affects reproductive-age women (20s-30s)
Classic triad: dysmenorrhea, dyspareunia, infertility ("3 Ds" + infertility)
Symptoms cyclically worse with menstruation
CA-125 may be mildly elevated

2. ADENOMYOSIS

Pathological Definition

Presence of endometrial glands and/or stroma within the myometrium (>2.5 mm below the basalis layer by convention), inducing reactive myometrial hypertrophy.

Gross Pathology

Uterus is symmetrically, diffusely enlarged (globular uterus) - may reach 200-300g (normal ~70g)
Cut surface: thickened uterine wall, trabeculated myometrium; small hemorrhagic cystic spaces may be visible (corresponding to ectopic glands)
No discrete fibroid nodule (unlike leiomyoma)
Poorly circumscribed - key differentiating feature from leiomyoma

Microscopic Pathology

Endometrial islands (glands + stroma) deep within myometrium, interposed between muscle bundles
Islands are typically basalis-type endometrium - do NOT respond to cyclical hormonal changes (unlike eutopic endometrium)
Surrounding smooth muscle shows reactive hypertrophy
May coexist with endometriosis (~15% of cases)

Molecular/Pathogenesis

Thought to arise from direct invagination of the basal endometrium into myometrium (invasion theory)
Associated with increased uterine peristalsis and trauma (multiparity, prior uterine surgery)
Estrogen-dependent (regresses after menopause)

Clinical Correlation

Affects multiparous women in late reproductive years (35-50)
Classic: secondary dysmenorrhea, menorrhagia, symmetrically enlarged tender uterus
Uterus is soft and boggy - "always bigger before menstruation and smaller after"
Definitive diagnosis only on hysterectomy specimen

3. ENDOMETRIAL HYPERPLASIA

Pathological Definition

Abnormal proliferation of endometrial glands relative to stroma, resulting in an increased gland-to-stroma ratio compared to normal proliferative endometrium - due to unopposed estrogen stimulation.

WHO Classification (Two Major Types)

Feature	Hyperplasia WITHOUT Atypia	Hyperplasia WITH Atypia (EIN)
Gland:stroma ratio	Increased	Markedly increased
Gland architecture	Variable size, dilated, back-to-back focally, some stroma retained	Complex, crowded, branching glands; cribriform/budding
Nuclear atypia	ABSENT - round/oval nuclei, uniform	PRESENT - enlarged, vesicular nuclei, prominent nucleoli, irregular chromatin
Mitoses	May be increased	Increased, may be abnormal
PTEN mutation	>20%	>20% (shared with carcinoma)
Risk of progression to carcinoma	1-3%	25-30% (considered precancerous = EIN)

Gross Pathology

Thickened, velvety, spongy endometrium
Polypoidal projections may be present
Proliferative type: pale, white-tan thickened mucosa
No myometrial invasion

Microscopic Pathology

Without atypia: increased G:S ratio, dilated cystic glands, back-to-back glands - NO cytologic atypia
With atypia (EIN): glandular crowding, nuclear enlargement, round/vesicular nuclei, prominent nucleoli, loss of polarity; may have confluent glandular growth approaching carcinoma
Stroma is compressed but present between glands (in contrast to carcinoma where stroma is replaced)

Molecular Pathogenesis

PTEN inactivation is the earliest molecular event - found in >20% of both subtypes
PI3K/AKT pathway overactivation
Microsatellite instability in some cases (MLH1 promoter methylation)
Lynch syndrome (germline MMR gene mutation) -> high lifetime risk
Cowden syndrome (germline PTEN mutation) -> high risk of both endometrial hyperplasia and carcinoma

Clinical Correlation

Perimenopausal women (45-55)
Presents with abnormal uterine bleeding (irregular, intermenstrual, postmenopausal)
Associated with obesity, PCOS, unopposed estrogen therapy, granulosa cell tumors
Diagnosed by endometrial biopsy / D&C

4. ENDOMETRIAL CARCINOMA

Pathological Definition

Malignant epithelial tumor of the endometrium; the most common gynecological cancer in high-income countries. Two major types with distinct pathogenesis:

TYPE I - Endometrioid Carcinoma (80%)

Gross Pathology

Exophytic, polypoid or infiltrative mass in endometrial cavity
Gray-white, friable, necrotic
Myometrial invasion - depth determines staging (confined to endometrium = stage IA; >50% myometrium = stage IB)
May extend to cervix (stage II), adnexa, parametrium (stage III)

Microscopic Pathology

Well-differentiated (grade 1): closely mimics proliferative endometrium; back-to-back tubular glands with minimal stroma; <5% solid growth
Grade 2: 6-50% solid growth; increasing atypia
Grade 3: >50% solid growth; marked nuclear atypia, large nucleoli
Myometrial invasion: irregular infiltrating glands with desmoplastic stroma - key feature
Squamous differentiation may occur (adenoacanthoma = benign squames; adenosquamous = malignant squames)
Immunostaining: ER+, PR+, vimentin+; p53 usually wild-type pattern

Molecular Pathogenesis

PTEN mutations (early event, 30-80%)
MMR gene mutations (MSI-H subtype)
PIK3CA mutations
KRAS, CTNNB1 (beta-catenin) mutations
Arises in background of endometrial hyperplasia with atypia (EIN)
Associated with Lynch syndrome (MLH1, MSH2 mutations)

TYPE II - Serous Carcinoma (15%)

Gross Pathology

Often arises on atrophic endometrium (no preceding hyperplasia)
Small primary tumor but early peritoneal spread
Papillary/exophytic growth

Microscopic Pathology

Small papillary tufts with complex branching; marked cytologic atypia
Hobnail cells, slit-like glandular spaces
High-grade by definition - marked nuclear pleomorphism, macronucleoli
Psammoma bodies in ~30%
Precursor lesion: Serous Endometrial Intraepithelial Carcinoma (SEIC) - morphologically malignant cells on atrophic endometrium
IHC: diffuse/strong p53+ (mutant pattern), WT1 often positive; ER/PR negative

Molecular Pathogenesis

TP53 mutation in nearly ALL cases (early event)
PTEN and MMR mutations rare
HER2 amplification in ~30%
Overlap with high-grade serous ovarian carcinoma
Associated with BRCA mutations

Clinical Correlation

Endometrioid: postmenopausal obese women, 55-65 years; risk factors = obesity, nulliparity, diabetes, HRT (unopposed estrogen), tamoxifen use
Serous: older, postmenopausal, 65-70 years; NOT associated with obesity/estrogen
Both present with postmenopausal bleeding (endometrial biopsy is gold standard)
Grade 1 endometrioid: 5-year survival ~90%; serous: poor prognosis due to advanced stage at presentation

5. ENDOMETRIAL STROMAL TUMOR

Pathological Definition

Neoplasms composed of cells resembling proliferative-phase endometrial stromal cells. Spectrum from benign to malignant.

Classification

Category	Behavior	Key Feature
Endometrial stromal nodule	Benign	Well-circumscribed, no vascular invasion
Low-grade endometrial stromal sarcoma (LG-ESS)	Low malignant potential	Infiltrating margins, lymphovascular invasion; recurs late
High-grade endometrial stromal sarcoma (HG-ESS)	Aggressive	High-grade round cell morphology; YWHAE fusion
Undifferentiated uterine sarcoma (UUS)	Highly aggressive	No endometrial stromal differentiation

Gross Pathology

Stromal nodule: discrete, well-circumscribed, yellow-tan, soft nodule in myometrium
LG-ESS: worm-like plugs of tumor extending into myometrial vessels and lymphatics - classic "Indian filing" pattern; cut surface shows yellow-tan bands permeating myometrium; ill-defined borders
HG-ESS/UUS: large fleshy hemorrhagic mass, necrosis

Microscopic Pathology

Stromal nodule and LG-ESS: uniform, small cells resembling proliferative-phase stromal cells - oval nuclei, scant cytoplasm, spiral arteriole-like vasculature (tongue-like projections into myometrium in LG-ESS)
LG-ESS: infiltrating margins with perivascular spread; low mitotic rate (<10/10 HPF); CD10+, ER+, PR+
HG-ESS: high-grade round to spindle cells, >10 mitoses/10 HPF; YWHAE-NUTM2 gene fusion; CD10 negative; cyclin D1 overexpression
UUS: pleomorphic, undifferentiated cells; no specific markers; diagnosis of exclusion

Molecular Pathogenesis

LG-ESS: JAZF1-SUZ12 fusion (most common, ~50%); PHF1-JAZF1 fusions also described
HG-ESS: YWHAE-NUTM2A/B fusion
CD10 expression reflects stromal origin

Clinical Correlation

Women in reproductive/perimenopausal age
Presents with abnormal uterine bleeding and pelvic pain; often found incidentally
LG-ESS: excellent prognosis with surgery; late recurrences after 5-10 years are characteristic; hormone-responsive (ER/PR+), responds to progestins/aromatase inhibitors
HG-ESS/UUS: aggressive, rapid progression

6. UTERINE LEIOMYOMA (FIBROID)

Pathological Definition

Benign smooth muscle neoplasm of the myometrium - the most common tumor in women overall. Estrogen and progesterone-dependent.

Gross Pathology

Multiple (vs. single) in most cases
Sharply circumscribed, firm, gray-white nodules with classic whorled cut surface
Well-delineated from surrounding myometrium (pseudocapsule)
Locations:
- Intramural (most common, within myometrium)
- Submucosal (beneath endometrium - most symptomatic; cause AUB)
- Subserosal (below serosa; may be pedunculated)
- Cervical, broad ligament, parasitic (rare)
Size: millimeters to 20+ cm
Secondary changes (degeneration):
- Hyaline degeneration (most common) - white, homogeneous areas
- Cystic degeneration - central liquefaction
- Red/carneous degeneration - hemorrhagic infarction (especially during pregnancy) - clinically presents as acute pain
- Calcification ("womb stone") - in postmenopausal women
- Myxoid degeneration

Microscopic Pathology

Interlacing bundles of uniform, bland smooth muscle cells - cigar-shaped nuclei, eosinophilic cytoplasm, no nuclear atypia
Low mitotic rate (<5 mitoses/10 HPF)
Hyalinized collagen between muscle bundles (in degenerating areas)
Absence of tumor cell necrosis
IHC: SMA+, desmin+, h-caldesmon+
Key distinction from leiomyosarcoma: leiomyosarcoma has nuclear atypia, >10 mitoses/10 HPF, and coagulative tumor cell necrosis ("Stanford criteria")

Molecular Pathogenesis

MED12 mutations in up to 70% (encodes RNA pol II transcription regulator)
Chromosomal rearrangements (6p21, 12q15 - HMGA2)
Estrogen receptor and progesterone receptor positive (hormone-dependent growth)
Shrink after menopause; grow rapidly in pregnancy
Recurrent chromosomal rearrangements similar to lipomas and endometrial polyps

Clinical Correlation

Women of reproductive age (30s-40s), more common in African-American women
May be asymptomatic (found incidentally on USS)
Symptomatic: menorrhagia (submucosal), pelvic pressure/bulk symptoms (large intramural/subserosal), urinary frequency/retention, dysmenorrhea
Infertility if submucosal or distorting cavity
Uterus: irregularly enlarged, firm, non-tender (unless red degeneration)

Summary Comparison Table

Parameter	Endometriosis	Adenomyosis	Endometrial Hyperplasia	Endometrial Carcinoma	Endometrial Stromal Tumor	Leiomyoma
Tissue of origin	Ectopic endometrium (outside uterus)	Endometrium invading myometrium	Endometrial glands + stroma (intrauterine)	Endometrial epithelium	Endometrial stroma	Myometrium (smooth muscle)
Uterine size	Normal (or enlarged if coexisting)	Symmetrically enlarged, globular	Normal or slightly enlarged	Enlarged	Variable	Irregularly enlarged
Gross appearance	Chocolate cysts, peritoneal implants, adhesions	Thickened wall, small hemorrhagic foci in myometrium	Thickened, velvety endometrium	Polypoid/infiltrative endometrial mass	Worm-like myometrial plugs / yellow-tan nodule	Whorled, firm, circumscribed nodule(s)
Microscopic hallmark	Glands + stroma + hemosiderin outside uterus	Endometrial islands in myometrium (basalis type)	Increased G:S ratio (with/without atypia)	Invasive carcinomatous glands with desmoplasia	Uniform stromal cells, spiral arterioles, vascular invasion (LG-ESS)	Interlacing bland smooth muscle bundles
Nuclear atypia	Absent	Absent	Absent (without atypia) / Present (EIN/with atypia)	Present (grade-dependent)	Low (LG-ESS) / High (HG-ESS)	Absent
Myometrial invasion	N/A (ectopic)	Present (defining feature)	Absent	Present (diagnostic of malignancy)	Present (LG-ESS by definition)	No true invasion (pseudocapsule)
Key molecular marker	Aromatase overexpression, VEGF	-	PTEN mutation (early)	PTEN, MMR (Type I); TP53 (Type II)	JAZF1-SUZ12 (LG-ESS); YWHAE-NUTM2 (HG-ESS)	MED12 mutation (70%)
IHC	ER+, PR+	ER+, PR+	ER+, PR+	ER/PR+ (Type I); p53++ (Type II)	CD10+, ER/PR+ (LG-ESS)	SMA+, desmin+, h-caldesmon+
Age group	Reproductive (20s-30s)	Late reproductive (35-50)	Perimenopausal (45-55)	Postmenopausal (55-65)	Reproductive/perimenopausal	Reproductive (30s-40s)
Typical bleeding pattern	Dysmenorrhea (cyclic)	Menorrhagia + secondary dysmenorrhea	AUB, intermenstrual	Postmenopausal bleeding	AUB	Menorrhagia (submucosal)
Malignant potential	Rare (ovarian endometrioma)	None	1-3% (without atypia); 25-30% (EIN)	Malignant by definition	Nodule: none; LG-ESS: low; HG-ESS: high	Very rare (<0.5%) -> leiomyosarcoma
Associated syndromes	-	-	Lynch, Cowden syndrome	Lynch syndrome, Cowden syndrome	-	-
Diagnosis	Laparoscopy (gold standard)	Hysterectomy specimen	Endometrial biopsy / D&C	Endometrial biopsy / D&C + staging	Hysterectomy + histology	Ultrasound + histology

Key Pathological Differentiating Points

Endometriosis vs. Adenomyosis: Both contain ectopic endometrial tissue, but endometriosis is outside the uterus (peritoneal cavity, ovaries) while adenomyosis is within the myometrium. In adenomyosis, the ectopic glands are basalis-type (do NOT show cyclical secretory change), while endometriosis glands do respond hormonally.

Adenomyosis vs. Leiomyoma: Adenomyosis causes diffuse, symmetric uterine enlargement with poorly defined boundaries; leiomyoma causes irregular enlargement with a discrete, whorled, circumscribed nodule on cut section. Leiomyoma is smooth muscle; adenomyosis contains endometrial glands within muscle.

Endometrial Hyperplasia vs. Carcinoma: The defining feature of carcinoma is stromal invasion - desmoplastic stroma surrounding infiltrating glands. In hyperplasia, even with marked crowding, there is no stromal invasion. EIN (hyperplasia with atypia) shares PTEN mutations with carcinoma but lacks invasion.

Endometrial Carcinoma (Type I vs. II): Type I (endometrioid) is estrogen-driven, arises from hyperplasia, has PTEN/MMR mutations, ER/PR+, good prognosis. Type II (serous) is NOT estrogen-driven, arises on atrophic endometrium, has universal TP53 mutations, ER/PR negative, aggressive behavior with early peritoneal spread.

Endometrial Stromal Tumor vs. Leiomyoma: Both arise in the uterine wall but from different cell types. LG-ESS shows tongue-like vascular invasion (unlike the pseudocapsule of leiomyoma), uniform small cells with spiral arterioles, CD10+. Leiomyoma shows interlacing smooth muscle bundles, SMA+/desmin+, no vascular invasion.

Endometrial Stromal Tumor vs. Endometrial Carcinoma: Stromal tumors are mesenchymal (stromal cells); carcinomas are epithelial (glandular). ESS: CD10+, cytokeratin negative. Carcinoma: cytokeratin+, EMA+, CD10 usually negative.

Sources: Robbins & Kumar Basic Pathology (9780323790185), pp. 689-693; Robbins, Cotran & Kumar Pathologic Basis of Disease (9780443264528), pp. 929-940

Phyllodes tumor , fibroadenoma , pagets disease of breast , fibrocystic disease of breast , breast carcinoma differential diagnosis clinical features and patholgy tablutation only

Finding Sources

Reading File

Finding Sources

Reading File

I now have all the material needed. Here is the complete tabulated differential diagnosis:

Differential Diagnosis: Breast Conditions - Clinical Features & Pathology

Sources: Robbins, Cotran & Kumar Pathologic Basis of Disease (9780443264528); Bailey & Love's Short Practice of Surgery 28th Ed (9780367548117); Tintinalli's Emergency Medicine (9781260019933)

TABLE 1: CLINICAL FEATURES

Parameter	Fibroadenoma	Phyllodes Tumor	Fibrocystic Disease	Paget's Disease of Breast	Breast Carcinoma
Age	15-25 yrs (peak); young women	>30 yrs (peak 6th decade; 10-20 yrs later than fibroadenoma)	Reproductive age (25-50 yrs)	Postmenopausal (usually >50 yrs)	>50 yrs (most common); younger if BRCA mutation
Onset	Gradual, slow growing	Rapidly growing, can become massive	Cyclic, waxes and wanes with menstrual cycle	Insidious; chronic skin change at nipple	Gradual (early) or rapid (aggressive subtypes)
Lump characteristics	Single (usually), firm, rubbery, smooth, well-defined, mobile ("breast mouse"); 2-3 cm	Large, bosselated (lobulated) surface, mobile on chest wall; can be massive; rarely fixes to skin until late	Multiple, bilateral, tender nodularity; ill-defined; may fluctuate in size	May or may not have palpable mass; if palpable - deep to nipple	Single, hard, irregular, painless mass; poorly mobile; may be fixed to skin or chest wall
Tenderness	Non-tender (usually)	Non-tender	Tender, cyclically worse pre-menstrually	Nipple/areola burning or itching	Usually non-tender (unless inflammatory carcinoma)
Skin changes	None	Skin ulceration possible (pressure necrosis) in very large tumors	None (excludes skin thickening, edema, discoloration)	Eczematoid, weeping, erythematous, scaly lesion of nipple/areola - persists despite topical treatment	Dimpling (skin tethering), peau d'orange (lymphatic obstruction), nipple retraction, skin fixation, ulceration
Nipple changes	None	None	None	Nipple erosion, crusting, oozing, bloody/serous discharge	Nipple retraction, discharge (bloody), Paget change (if DCIS involves nipple ducts)
Lymph nodes	Not enlarged	Axillary spread RARE (even malignant type spreads hematogenously)	Not enlarged	May be involved if underlying invasive carcinoma present	Axillary LN enlargement (hard, fixed in advanced disease)
Bilaterality	Usually unilateral; can be bilateral	Unilateral	Bilateral (hallmark)	Unilateral	Usually unilateral (bilateral in LCIS or multifocal disease)
Multiplicity	Usually solitary; giant or multiple variants exist	Usually solitary	Multiple bilateral cysts and nodules	Single nipple/areola lesion	Usually solitary; multifocal/multicentric possible
Cyclical variation	None	None	Yes - symptoms worsen with menstruation	None	None
Associated features	-	-	Mastalgia, lumpy breast, occasional nipple discharge	Delayed diagnosis (6-12 months) due to resemblance to eczema/dermatitis	Weight loss, metastatic signs (bone pain, breathlessness) in advanced disease
Mammography	Well-circumscribed, radiopaque mass; may have coarse "popcorn" calcifications	Large, well-defined mass; leaf-like architecture on imaging	Multiple cysts, diffuse density changes	Subareolar mass/DCIS pattern; skin thickening at nipple	Spiculated/irregular radiodense mass; microcalcifications (DCIS); architectural distortion
Diagnosis	Ultrasound + FNAC/biopsy; clinical if typical features in young woman	Core biopsy/excision (FNA inadequate); margin assessment	Clinical + USS; biopsy if solid component	Punch biopsy of nipple (Paget cells); bilateral mammography	Core needle biopsy (gold standard); FNAC; excision biopsy
Malignant potential	Low (RR 1.5-1.7); complex type RR 3-4	Benign 75%: no mets; Malignant: hematogenous mets ~30%	Depends on subtype (see pathology table)	Nearly 100% associated with underlying DCIS or invasive carcinoma	Malignant by definition

TABLE 2: GROSS PATHOLOGY

Parameter	Fibroadenoma	Phyllodes Tumor	Fibrocystic Disease	Paget's Disease	Breast Carcinoma
Size	2-3 cm (most); giant >5 cm (in adolescents)	Few cm to massive (entire breast); largest of all breast tumors	Variable cysts (small to several cm)	Nipple/areola lesion - small skin lesion	2-3 cm at presentation (if no screening); <1 cm if screen-detected
Shape	Round/oval, smooth, well-circumscribed	Large, bosselated, lobulated; "leaf-like" protrusions on cut surface (phyllodes = Greek for "leaf")	Multiple irregular cysts; thickened, rubbery breast tissue	Erythematous, weeping eczematoid nipple lesion; may have underlying mass	Irregular, stellate/spiculated; "crab-like" (carcinoma = crab in Greek)
Consistency	Firm, rubbery	Fleshy, soft to firm; hemorrhagic/necrotic in malignant type	Cysts: fluctuant; fibrotic areas: firm	Crusted, erythematous skin surface at nipple	Hard (scirrhous); grating on cut surface due to desmoplastic stroma and calcifications
Margins	Sharp, well-defined capsule; well-circumscribed	Benign: circumscribed; Malignant: widely infiltrative, ill-defined	No discrete capsule; diffuse	Skin-based; no discrete mass unless underlying carcinoma	Irregular, infiltrative margins; no capsule
Cut surface	Rubbery, white/gray; no necrosis; no adipose tissue (radiodense)	Cleft-like spaces / leaf-like projections of stroma covered by epithelium protruding into cystic spaces	Multiple cysts (blue-domed cysts = apocrine lined); fibrous stroma	Skin thickening/ulceration at nipple; underlying DCIS not grossly visible	Gray-white chalky desmoplastic areas; foci of necrosis (comedo type); chalky-white streaks; occasional grating on cutting
Mobility	Highly mobile (pseudocapsule - moves freely)	Mobile (even when large); does NOT fix to chest wall until very late	Not a discrete mobile mass	-	Fixed or restricted mobility (skin/chest wall fixation in advanced disease)
Necrosis	Absent	Present in malignant phyllodes	Absent	Absent	Present (comedo necrosis in high-grade DCIS; central necrosis in high-grade invasive)

TABLE 3: MICROSCOPIC (HISTOLOGICAL) PATHOLOGY

Parameter	Fibroadenoma	Phyllodes Tumor	Fibrocystic Disease	Paget's Disease	Breast Carcinoma
Tissue of origin	Intralobular stroma (biphasic - stroma + epithelium)	Intralobular stroma (biphasic - more cellular stroma)	Terminal duct-lobular unit (TDLU)	Lactiferous ducts -> epidermis of nipple	Ductal or lobular epithelium
Key histological pattern	Intralobular stroma surrounds, pushes, and distorts epithelial tubules; pericanalicular (stroma encircles glands) or intracanalicular (stroma compresses glands into slits) pattern	Leaf-like fronds of hypercellular stroma covered by epithelium projecting into cystic spaces; stroma dominates	Cysts (apocrine metaplasia lining), adenosis (lobular enlargement), fibrosis (dense stromal collagen), epithelial hyperplasia	Paget cells: large, pale, vacuolated intraepidermal adenocarcinoma cells within squamous epithelium of nipple, without crossing basement membrane - DCIS extending up lactiferous ducts into skin	Invasive carcinoma NST: irregular infiltrating glands/nests/cords/solid sheets with desmoplastic stroma; Lobular: single-file ("Indian file") infiltration; Tubular: well-formed open tubules
Stromal cellularity	Low; loose myxoid or fibrous stroma	Increased (benign < borderline < malignant); key distinguishing feature from fibroadenoma	Variable fibrosis; no atypical stromal cells	Absent (skin lesion)	Desmoplastic fibrous stroma (reactive); angiofibrotic stroma
Nuclear atypia	Absent (bland, uniform)	Benign: minimal; Borderline: moderate; Malignant: marked pleomorphism	Absent in simple changes; present in atypical ductal/lobular hyperplasia	Paget cells: large, round nuclei, prominent nucleoli, pale cytoplasm, mucin-containing vacuoles	Grade 1: minimal; Grade 2: moderate; Grade 3: marked, irregular, large nuclei, prominent nucleoli
Mitotic rate	Very low (<3/10 HPF)	Benign: <4/10 HPF; Borderline: 4-9/10 HPF; Malignant: >10/10 HPF	Absent/rare	Absent (in Paget cells) to present if underlying invasive carcinoma	Variable; Grade 3: high; Grade 1: low
Margins/Invasion	No invasion; pushes surrounding tissue	Benign: pushing; Malignant: infiltrating into surrounding breast parenchyma	No invasion	Paget cells remain above basement membrane (intraepidermal); DCIS component is in situ	Basement membrane disruption - invasive carcinoma crosses BM into stroma
Basement membrane	Intact	Intact (benign); disrupted (malignant)	Intact	Intact (Paget cells are intraepidermal, do NOT invade dermis - unlike melanoma)	Disrupted (defining feature of invasive carcinoma)
Necrosis	Absent	Absent (benign); Present (malignant)	Absent	Absent	Comedo necrosis (high-grade DCIS); present in grade 3 invasive carcinoma
Calcifications	May be present (coarse, "popcorn")	May be present	Psammomatous or lobular calcifications	Absent (in nipple skin)	Microcalcifications (DCIS: linear/branching or casting type); present in ~50% of invasive carcinomas
Special cell types	-	-	Apocrine metaplasia (columnar, pink, granular cytoplasm); foam cells in cyst fluid	Paget cells: PAS+, mucin+, CK7+, HER2+ (often); GATA3+	Invasive NST: no specific cell type; Mucinous: lakes of mucin; Lobular: discohesive cells with intracytoplasmic mucin vacuoles (signet ring)

TABLE 4: MOLECULAR / IHC / PATHOGENESIS

Parameter	Fibroadenoma	Phyllodes Tumor	Fibrocystic Disease	Paget's Disease	Breast Carcinoma
Key molecular alteration	MED12 mutation (2/3 of cases) - transcriptional regulator; same as uterine leiomyoma	MED12 + RARA mutations (shared with fibroadenoma); additionally TERT, TP53, RB mutations in malignant type	Estrogen/progesterone imbalance; no driver mutations in simple lesions; PTEN in atypical hyperplasia	HER2 overexpression (>90% of cases); associated with underlying HER2+ DCIS/invasive carcinoma	Luminal (ER/PR+): PTEN, PIK3CA, GATA3 mutations; HER2: HER2 amplification; TNBC: BRCA1, TP53 mutations
IHC markers	ER+, PR+ (epithelial component); CD34+ (stroma)	CD34+ (stroma); ER/PR variable; p53 + in malignant type	ER+, PR+	CK7+, HER2+ (>90%), GATA3+, mucin (PAS+); S100-, HMB45- (distinguishes from melanoma)	Luminal: ER+, PR+, HER2-; HER2+: ER-, HER2+++; TNBC: ER-, PR-, HER2- (triple negative); CK5/6+, EGFR+
Hormone sensitivity	Estrogen-dependent growth; may enlarge in pregnancy; involutes post-menopause	Variable	Estrogen excess; responds to cyclic hormonal changes	Not hormonally driven	ER+ (~70%): estrogen-driven growth; responds to anti-estrogen therapy
Hereditary association	Carney complex (myxoid type - PRKAR1A mutation)	-	-	-	BRCA1/BRCA2 (10% of all breast cancers); Lynch syndrome; Li-Fraumeni (TP53); Cowden syndrome (PTEN)
Risk of malignancy	Simple: RR 1.5-1.7; Complex (with epithelial hyperplasia + family Hx): RR 3.0-4.0	Benign: no mets, can recur locally; Malignant: hematogenous mets ~30% (NOT lymphatic - LN dissection contraindicated)	No atypia: no increased risk; Usual ductal hyperplasia: RR 1.5-2; Atypical ductal/lobular hyperplasia: RR 4-5; ADH + family Hx: RR ~10	Nearly 100% have underlying DCIS; ~50% have invasive carcinoma (when palpable mass present)	Malignant

TABLE 5: QUICK-REFERENCE SUMMARY (Key Distinguishing Features)

Feature	Fibroadenoma	Phyllodes Tumor	Fibrocystic Disease	Paget's Disease	Breast Carcinoma
Nature	Benign biphasic tumor	Biphasic tumor (benign/borderline/malignant)	Benign fibrocystic change	Intraepidermal carcinoma (almost always with underlying DCIS/invasive Ca)	Malignant epithelial tumor
Classic age	15-25 yrs	>30 yrs (6th decade)	25-50 yrs	Postmenopausal	>50 yrs
Classic lump	Mobile, rubbery, well-defined ("breast mouse")	Large, bosselated, rapidly growing	Bilateral, tender nodularity; no discrete lump	Nipple/areola lesion (weeping, eczematoid)	Hard, irregular, fixed, painless
Bilateral	Usually No	No	Yes	No	Usually No
Cyclical symptoms	No	No	Yes	No	No
Skin/nipple	Normal	Ulceration (pressure) if huge	Normal	Eczematoid nipple - diagnostic	Dimpling, peau d'orange, nipple retraction
Margins (micro)	Circumscribed, pushing	Circumscribed (benign) / Infiltrative (malignant)	Diffuse, no margins	Intraepidermal (above BM)	Invasive (crosses BM)
Stroma	Scant, myxoid	Hypercellular with atypia	Fibrotic	-	Desmoplastic
Mitoses	<3/HPF	<4 (benign), 4-9 (borderline), >10 (malignant)	Absent	Absent	High in grade 3
Key IHC	CD34+, ER+	CD34+, p53+ (malignant)	ER+	CK7+, HER2+ (>90%)	ER/PR/HER2 (molecular subtype)
Key mutation	MED12	MED12+RARA+TERT/TP53	-	-	BRCA1/2, TP53, PIK3CA, PTEN
Metastasis	Never	Hematogenous only (malignant, ~30%)	Never	Depends on underlying invasive component	Lymphatic + hematogenous
Treatment	Conservative / excision if >3 cm or atypical	Wide local excision (2 cm margin); NO axillary LN dissection	Symptomatic; reassurance; biopsy if suspicious	Excision ± mastectomy depending on extent of DCIS	Surgery + RT + chemotherapy + endocrine/targeted therapy

Make a clinical decision flowchart for breast lesion diagnosis

Reading File

I'll generate a clean, detailed clinical decision flowchart as an image - that's the most direct and visually clear format for a flowchart.

Generating Image

A detailed clinical decision flowchart for breast lesion diagnosis. The flowchart starts at the top with "BREAST LESION / COMPLAINT" and branches through the following decision pathway: Step 1: Clinical Presentation Three branches from the top: - Left: "Nipple/areola skin change (eczematoid, weeping, crusting)" - Center: "Breast lump / mass" - Right: "Bilateral tender nodularity + cyclic pain" The RIGHT branch leads directly to a diagnosis box: "FIBROCYSTIC DISEASE - Reassure, analgesia, follow-up mammography" The LEFT branch leads to: "Punch biopsy of nipple" → "Paget cells (CK7+, HER2+, large pale intraepidermal cells)?" → YES → "PAGET'S DISEASE OF BREAST → Bilateral mammography → Underlying DCIS (50%) or Invasive Carcinoma (50%) → Staging & treatment" The CENTER "Breast lump" branch goes to Step 2: Patient Age - Branch A: Age 15-25 years - Branch B: Age 25-50 years - Branch C: Age >50 years / Postmenopausal Branch A (15-25 yrs): → Ultrasound → "Well-defined, homogeneous, hypoechoic oval mass?" → YES → FNAC/Core biopsy → "Bland biphasic proliferation, pushing margins, MED12 mutation" → FIBROADENOMA → Conservative management or excision if >3cm Branch B (25-50 yrs): → Triple Assessment: Clinical + Mammography/USS + Core Biopsy → "Large, bosselated, rapidly growing?" → YES → Core biopsy → "Hypercellular stroma, leaf-like fronds, increased mitoses" → PHYLLODES TUMOR → Grade (Benign/Borderline/Malignant) → Wide local excision 2cm margin, NO axillary dissection Branch C (>50 yrs / Postmenopausal): → "Hard, irregular, fixed, painless mass?" → YES → Mammography → "Spiculated mass / microcalcifications?" → YES → Core needle biopsy → "Invasive carcinoma - desmoplastic stroma, infiltrating glands, broken basement membrane" → BREAST CARCINOMA → IHC: ER/PR/HER2 → Molecular subtype → Staging (TNM) → Multidisciplinary treatment At the bottom: A summary legend box with color coding: - Green boxes: Benign conditions (Fibroadenoma, Fibrocystic Disease) - Orange boxes: Potentially malignant (Phyllodes, Paget's) - Red boxes: Malignant (Breast Carcinoma) - Blue boxes: Investigations - Gray boxes: Decision points The flowchart uses clean arrows, distinct colored boxes, professional medical typography, white background, clearly labeled investigation steps at each decision point. Include a small note at bottom: "Triple Assessment = Clinical Examination + Imaging + Histopathology"

Here is a text-based version of the full flowchart logic for reference:

CLINICAL DECISION FLOWCHART: BREAST LESION DIAGNOSIS

                        BREAST LESION / COMPLAINT
                               |
          ┌────────────────────┼──────────────────────┐
          ▼                    ▼                       ▼
  Nipple/Areola          Breast Lump/Mass         Bilateral Tender
  Skin Change                                     Nodularity + Cyclic
  (eczematoid,                                    Pain / Mastalgia
  weeping, crusting)                                    │
          │                                             ▼
          ▼                                    FIBROCYSTIC DISEASE
  Punch Biopsy Nipple                         Reassure + analgesia
          │                                   Mammography follow-up
          ▼
  Paget cells? (CK7+, HER2+,
  large pale intraepidermal
  vacuolated cells)
          │
    YES ──┤
          ▼
  PAGET'S DISEASE OF BREAST
  → Bilateral Mammography
  → Palpable mass?
    - NO: Underlying DCIS → BCS + RT
    - YES: Underlying Invasive Ca → Staging + MDT

              BREAST LUMP - TRIPLE ASSESSMENT
        (Clinical + Imaging + Histopathology)
                          │
         ┌────────────────┼────────────────┐
         ▼                ▼                ▼
      Age 15-25         Age 25-50       Age >50 / PMB

         │                │                │
         ▼                ▼                ▼
    Ultrasound       Triple Assessment   Mammogram
    (preferred        (MMG + USS +       (spiculated
    over MMG in       core biopsy)       mass /
    young women)                         microcalcifications?)
         │                │                │
         ▼                ▼                ▼
   Well-defined,    Large, bosselated,   Hard, irregular,
   smooth,          rapidly growing,     fixed, painless
   homogeneous      mobile mass          mass
   oval mass?
         │                │                │
    FNAC/Core          Core Biopsy       Core Needle Biopsy
    Biopsy                │              (MANDATORY)
         │                │                │
         ▼                ▼                ▼
   Bland biphasic    Hypercellular     Invasive carcinoma
   proliferation,    stroma, leaf-     (broken BM,
   pushing margins,  like fronds,      desmoplastic stroma,
   MED12 mutation    mitoses counted   infiltrating glands)
         │                │                │
         ▼                ▼                ▼
   FIBROADENOMA      PHYLLODES TUMOR   BREAST CARCINOMA
         │                │                │
    <3 cm: observe   Grade:            IHC: ER / PR / HER2
    >3 cm: excise    Benign (<4/HPF)          │
    Giant: enucleate Border (4-9/HPF)   ┌────┴─────────┐
    Complex + FHx:   Malignant(>10/HPF) │              │
    close follow-up        │          Luminal      HER2 / TNBC
                           ▼            │              │
                  WLE (2 cm margin)   Endocrine    Chemo ±
                  NO axillary LN      therapy +    Targeted
                  dissection          surgery      therapy
                  Malignant: monitor              + surgery
                  for hematogenous mets

Key Rule - Triple Assessment

Every discrete breast mass requires all three arms:

Arm	Tool
1. Clinical	Inspection + palpation (size, mobility, skin, LN)
2. Imaging	USS (<35 yrs) / Mammography (>35 yrs) / MRI (high-risk)
3. Histology	Core needle biopsy (preferred) or FNAC

Concordance of all three = definitive diagnosis. Discordance = repeat biopsy / excision.

Lung carcinoma differential diagnosis

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

I now have comprehensive material from Robbins Basic Pathology and Fishman's Pulmonary Diseases. Here is the complete tabulated differential diagnosis:

Lung Carcinoma: Differential Diagnosis - Clinical Features & Pathology

Sources: Robbins & Kumar Basic Pathology (9780323790185); Fishman's Pulmonary Diseases and Disorders (9781260473940)

TABLE 1: OVERVIEW & EPIDEMIOLOGY

Parameter	Squamous Cell Carcinoma	Adenocarcinoma	Large Cell Carcinoma	Small Cell Carcinoma (SCLC)	Carcinoid Tumor	Large Cell Neuroendocrine Carcinoma (LCNEC)
Frequency	~25-30%	Most common (~40%)	~10-15%	~13%	~1-2%	~3% of NSCLC
WHO 2021 Group	NSCLC	NSCLC	NSCLC	SCLC / Neuroendocrine	Neuroendocrine (low/intermediate grade)	High-grade neuroendocrine
Smoking association	Strongest (almost exclusively smokers)	Moderate (also non-smokers, women, young)	Strong	Very strong (reconsider diagnosis if non-smoker)	None / Weak	Strong
Peak age	50-70 yrs	50-70 yrs (also <45 yrs)	50-70 yrs	50-70 yrs	Any age (typical carcinoid: young adults)	50-70 yrs
Sex predilection	Male > Female	Female ≥ Male (rising in women); most common in never-smokers	Male > Female	Male > Female	No strong sex predilection	Male > Female

TABLE 2: LOCATION & GROSS PATHOLOGY

Parameter	Squamous Cell Carcinoma	Adenocarcinoma	Large Cell Carcinoma	Small Cell Carcinoma	Carcinoid Tumor	LCNEC
Location	Central (hilar, main/lobar bronchi)	Peripheral (subpleural, distal bronchioles/alveoli)	Peripheral (usually)	Central (perihilar, mediastinal)	Central (80%) or peripheral	Central or peripheral
Gross appearance	Gray-white, firm, cavitating mass at hilum; necrotic center; may involve bronchus with mucosal thickening	Gray-white peripheral nodule, "scar cancer" appearance; may have pleural puckering; no cavitation (usually)	Large, fleshy, necrotic peripheral mass; no distinctive gross features	Soft, white, fish-flesh perihilar mass; extensive mediastinal involvement; marked nodal enlargement	Well-circumscribed, tan-yellow, intrabronchial polypoid lesion; smooth surface; rarely necrotic	Large fleshy mass, necrosis, may cavitate
Cavitation	Common (central necrosis)	Rare	Rare	Rare (too rapid growth)	Absent	Occasional
Pleural involvement	Less common (central)	Common (peripheral - pleural puckering, effusion)	Common (peripheral)	Pericardial/pleural effusion (mediastinal spread)	Rare	Variable
Size	Large central mass	1-5 cm (peripheral); lepidic type may be diffuse	Large (>3 cm usually)	Large mediastinal mass with hilar widening	Small (1-3 cm), well-defined	Variable, often large

TABLE 3: MICROSCOPIC PATHOLOGY

Parameter	Squamous Cell Carcinoma	Adenocarcinoma	Large Cell Carcinoma	Small Cell Carcinoma	Carcinoid Tumor	LCNEC
Cell of origin	Bronchial squamous epithelium (via squamous metaplasia)	Bronchiolar/alveolar epithelium, Clara cells, bronchioalveolar stem cells	Undifferentiated large epithelial cells	Neuroendocrine cells (Kulchitsky cells) of bronchial epithelium	Neuroendocrine cells (Kulchitsky cells)	Neuroendocrine cells
Cell size	Large, polygonal	Variable; columnar/cuboidal	Large (>3 lymphocyte diameters)	Small (<3 lymphocyte diameters); oval/spindle	Medium-sized, uniform, round-oval	Large (>3 lymphocyte diameters)
Cytoplasm	Abundant, eosinophilic, keratinized	Variable; may be vacuolated (mucin-containing)	Abundant	Scant (key feature)	Moderate, granular, eosinophilic	Moderate to abundant
Nuclei	Large, hyperchromatic; intercellular bridges	Vesicular; prominent nucleoli	Large, vesicular, prominent nucleoli	Finely granular "salt & pepper" chromatin; nuclear molding; absent/inconspicuous nucleoli	Round, uniform, "salt & pepper" chromatin; no nucleoli	Vesicular chromatin; frequent prominent nucleoli (key distinction from SCLC)
Key histologic pattern	Keratinization (keratin pearls, individual cell keratinization); intercellular bridges; stratified squamous growth	Acinar, papillary, micropapillary, solid, or lepidic (growth along alveolar walls without invasion - AIS pattern); mucin production	Sheets/nests of large undifferentiated cells; no glands, keratin, neuroendocrine features	Sheets of small cells; nuclear molding; crush artifact (Azzopardi effect - DNA encrustation of vessel walls); extensive necrosis	Organoid nesting, trabecular, insular patterns; uniform "salt & pepper" chromatin; ≤2 mitoses/2mm² (typical) or 2-10 (atypical)	Organoid nesting, trabecular, rosette-like, palisading patterns with LARGE cells; necrosis; >10 mitoses/2mm²
Necrosis	Central necrosis (causes cavitation)	Occasional	Present	Extensive, coagulative	Absent (typical); may be present in atypical	Prominent
Mitotic rate	Variable (moderate)	Variable	High	Very high (avg >60 mitoses/2mm²)	Typical: ≤2/2mm²; Atypical: 2-10/2mm²	>10 mitoses/2mm² (defining criterion)
Precursor lesion	Squamous dysplasia → CIS (central airways)	Atypical adenomatous hyperplasia (AAH) → AIS → minimally invasive adenocarcinoma → invasive adenocarcinoma	No defined precursor	DIPNECH (diffuse idiopathic pulmonary neuroendocrine cell hyperplasia)	DIPNECH	-

TABLE 4: IHC & MOLECULAR MARKERS

Marker	Squamous Cell Ca	Adenocarcinoma	Large Cell Ca	Small Cell Ca	Carcinoid	LCNEC
CK5/6	+	-	-	-	-	-
p40 / p63	+	-	-	-	-	-
TTF-1	-	+ (75-85%)	-	+ (90%)	+/-	+/-
Napsin A	-	+	-	-	-	-
Synaptophysin	-	-	-	+	+	+
Chromogranin A	-	-	-	+	+	+
CD56	-	-	-	+	+	+
Ki-67	Intermediate	Intermediate	High	Very high (>50-80%)	Low (<20% typical; 20-40% atypical)	High (>40%)
p53	Frequent	Less common	-	Very common	Rare	Common
Key driver mutations	TP53, CDKN2A, SOX2, FGFR1	EGFR (10-15% Western; 30-40% Asian), KRAS (30%), ALK fusion (4-6%), ROS1, HER2, MET, BRAF	TP53, various	TP53, RB1, MYC amplification	MEN1 (familial), sporadic	RB1, TP53 (similar to SCLC)
Molecular subtype relevance	PDL1 expression (immunotherapy); FGFR1 amplification (targeted)	EGFR/ALK/ROS1/KRAS targeted therapy	PDL1 high in some	Rarely targetable	MEN-1 gene (familial)	SCLC-like treatment often used

TABLE 5: CLINICAL FEATURES & PRESENTATION

Parameter	Squamous Cell Ca	Adenocarcinoma	Large Cell Ca	Small Cell Ca	Carcinoid	LCNEC
Typical presentation	Cough, hemoptysis, post-obstructive pneumonia (central)	Often asymptomatic initially (peripheral); pleural effusion; dyspnea	Late-presenting large peripheral mass; non-specific symptoms	Rapidly progressive cough, dyspnea, wheezing, hemoptysis, mediastinal symptoms	Episodic hemoptysis, recurrent pneumonia, wheeze (central); incidental nodule (peripheral)	Aggressive like SCLC; cough, dyspnea, weight loss
Hemoptysis	Common (central, ulcerates bronchus)	Less common	Variable	Common	Common (vascular polypoid lesion)	Variable
Obstructive symptoms	Common (endobronchial growth -> lobar collapse, post-obstructive pneumonitis)	Less common	Rare	Very common (massive mediastinal adenopathy)	Common (central intrabronchial polyp)	Variable
Superior vena cava syndrome	Occasional	Rare	Rare	Classic (massive mediastinal involvement)	Rare	Rare
Pancoast tumor	Can occur (apical)	Can occur (apical)	Can occur	Rare	Rare	Rare
Horner syndrome	Apical (Pancoast)	Apical (Pancoast)	Rare	Mediastinal invasion	Rare	Rare
Pleural effusion	Less common	Common (peripheral, pleural seeding)	Common	Pericardial + pleural	Rare	Variable
Metastasis pattern	Regional LN, bone, liver, brain, adrenal	Bone, brain, liver, adrenal, pleural seeding	Brain, liver, bone	Widespread early: brain, bone, liver, adrenal (>50% at presentation)	Rare (typical); liver mets (atypical)	Brain, liver, bone

TABLE 6: PARANEOPLASTIC SYNDROMES

Syndrome	Squamous Cell Ca	Adenocarcinoma	Large Cell Ca	Small Cell Ca	Carcinoid	LCNEC
Hypercalcemia (PTHrP)	Classic	-	Rare	-	-	-
SIADH (ADH secretion)	Rare	Rare	Rare	Classic	-	-
Cushing syndrome (ectopic ACTH)	Rare	Rare	Rare	Classic	Rare	Rare
Eaton-Lambert syndrome (anti-VGCC)	-	-	-	Classic	-	-
Carcinoid syndrome (5-HT, histamine)	-	-	-	-	Classic (liver mets required for typical carcinoid)	-
Hypertrophic pulmonary osteoarthropathy	Common	Common	Variable	Rare	Rare	Rare
Gynecomastia (HCG)	-	-	Classic (large cell)	-	-	-
Trousseau syndrome (migratory thrombophlebitis)	-	Classic (adenocarcinoma, mucin)	-	-	-	-

TABLE 7: RADIOLOGY & STAGING

Parameter	Squamous Cell Ca	Adenocarcinoma	Large Cell Ca	Small Cell Ca	Carcinoid	LCNEC
CXR pattern	Central hilar mass, lobar collapse, cavitating lesion	Peripheral nodule/mass, pleural effusion, "ground glass" (AIS)	Large peripheral opacification	Hilar/mediastinal widening, bilateral	Coin lesion, well-defined oval/round endobronchial mass	Large peripheral mass
CT features	Spiculated or lobulated central mass; luminal narrowing; post-obstructive consolidation	Spiculated peripheral mass; "ground glass" with solid component (part-solid); pleural retraction	Large necrotic peripheral mass	Large central mass with extensive mediastinal/hilar LN; may have SVC compression	Well-defined, homogeneous, non-calcified nodule; may see "sail sign" (intralobar atelectasis)	Large mass, often with necrosis
PET-FDG	High avidity	High avidity	High avidity	High avidity	Low/variable avidity (low-grade carcinoids may be FDG-negative; use octreotide scan/68Ga-DOTATATE instead)	High avidity
Staging system	TNM (8th ed AJCC/IASLC)	TNM	TNM	TNM (also IASLC limited vs extensive stage for treatment)	TNM	TNM
Resectability	If NSCLC stages I-IIIA: resectable	If NSCLC stages I-IIIA: resectable	If NSCLC stages I-IIIA: resectable	Rarely resectable (<10%); chemotherapy is primary treatment	Resectable (most typical carcinoids); surgical cure common	Often not resectable

TABLE 8: PROGNOSIS & TREATMENT

Parameter	Squamous Cell Ca	Adenocarcinoma	Large Cell Ca	Small Cell Ca	Carcinoid	LCNEC
5-year survival (all stages)	~15-20%	~20-25% (better with targeted therapy)	~10-15%	<5% (extensive); ~20% (limited)	Typical: >90%; Atypical: ~60-70%	~15-30%
Primary treatment	Surgery (I-III); RT + Chemo (III); Immunotherapy (PDL1+)	Surgery (I-IIIA); EGFR/ALK/ROS1 inhibitors; Immunotherapy; Chemotherapy	Surgery (early); Chemo ± RT (advanced)	Chemotherapy (etoposide + cisplatin/carboplatin) + RT; PCI (prophylactic cranial irradiation if limited stage)	Surgical resection (lobectomy/sleeve resection); somatostatin analogues (symptomatic/metastatic)	SCLC-like chemo regimens; surgery if resectable
Targeted therapy	FGFR1, MET (limited); Pembrolizumab	EGFR (gefitinib, erlotinib, osimertinib); ALK (crizotinib, alectinib); ROS1 (crizotinib); KRAS G12C (sotorasib); BRAF (dabrafenib)	Immunotherapy (PD-L1)	Atezolizumab + chemo (1st line)	Somatostatin analogues (octreotide, lanreotide); everolimus	Limited
Key distinguishing prognostic factor	Stage + PDL1 expression	Driver mutation status (EGFR/ALK)	Stage	Extremely chemosensitive but almost always relapses	Grade (typical vs atypical carcinoid)	Poor prognosis overall

QUICK SUMMARY TABLE: KEY DIFFERENTIATING FEATURES

Feature	SCC	Adeno	Large Cell	SCLC	Carcinoid	LCNEC
Location	Central	Peripheral	Peripheral	Central	Central (80%)	Any
Smoking	+++	++ (also non-smokers)	++	+++	-	++
Cavitation	Yes	No	No	No	No	Occasional
Keratin pearls	Yes	No	No	No	No	No
Nuclear molding	No	No	No	Yes	No	No
"Salt & pepper" chromatin	No	No	No	Yes	Yes	Coarse
Mucin production	No	Yes	No	No	No	No
TTF-1	-	+	-	+	+/-	+/-
Synaptophysin/CD56	-	-	-	+	+	+
Key paraneoplastic	Hypercalcemia	Trousseau	Gynecomastia	SIADH, Cushing, Eaton-Lambert	Carcinoid syndrome	-
Key mutation	TP53, SOX2	EGFR, KRAS, ALK	TP53	RB1, TP53	MEN1	RB1, TP53
Prognosis	Intermediate	Best (targeted Rx)	Poor	Worst	Best	Poor

Sources: Robbins & Kumar Basic Pathology (9780323790185), pp. 485-491; Fishman's Pulmonary Diseases and Disorders (9781260473940), pp. 560-562, 1972-1973

This is a shared conversation. Sign in to Orris to start your own chat.